Clinical trials: Fibrosarcoma NOS
MPNST (Malignant Peripheral Nerve Sheath Tumor)
Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor
The purpose of this study is to learn whether the study drugs avutometinib and defactinib can help stop or shrink malignant peripheral nerve sheath tumors (MPNST) that have returned or cannot be removed with surgery.
- Trial name
- NF120 (NCT07743554)
- Testing
- avutometinib capsule + defactinib tablet
- Volunteers
- 25 people
- Sponsor
- Girish Dhall, MD
Sarcoma
Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether ifosfamide or doxorubicin is more effective for advanced or metastatic soft…
- Trial name
- NCT00003212
- Testing
- doxorubicin hydrochloride, ifosfamide
- Where
- 23 sites in Belgium, Denmark and 8 more
- Volunteers
- 780 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
This is a multicenter open-label, randomized, non-comparative, parallel cohort pivotal study of treatment with envafolimab (cohort A and C) or envafolimab combined with ipilimumab (cohort B and D) in patients with locally…
- Trial name
- ENVASARC (NCT04480502)
- Testing
- Envafolimab, Ipilimumab
- Where
- 30 sites in United States, United Kingdom
- Volunteers
- 207 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have…
- Trial name
- NCT00031915
- Testing
- imatinib mesylate
- Where
- 10 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
This phase I trial is studying the side effects and best dose of cixutumumab given together with doxorubicin hydrochloride and to see how well they work in treating patients with unresectable, locally advanced, or metastatic soft…
- Conditions
- Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma
- Trial name
- NCT00720174
- Testing
- Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Pediatric Solid Tumor, Germ Cell Tumor
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of…
- Conditions
- Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma
- Trial name
- NCT04483778
- Testing
- second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG, Pembrolizumab
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Seattle Children's Hospital
Ewing Sarcoma, Myxoid Liposarcoma
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Single agent, non-randomized, open label expansion in select sarcoma patients including myxoid liposarcoma and other sarcomas that share similar chromosomal translocations to Ewing sarcoma; AND dose expansion of the combination…
- Conditions
- Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor
- Trial name
- NCT03600649
- Testing
- Seclidemstat, Cyclophosphamide, Topotecan
- Where
- 16 sites in United States
- Volunteers
- 50 people
- Sponsor
- Salarius Pharmaceuticals, LLC
Central Nervous System Neoplasm, Infantile Fibrosarcoma
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back.
- Conditions
- Central Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia
- Trial name
- NCT03834961
- Testing
- Larotrectinib Sulfate
- Where
- 80 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- Children's Oncology Group
Neurofibromatosis Type 1, Sarcoma
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00304083
- Testing
- filgrastim, doxorubicin hydrochloride, etoposide
- Where
- 17 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Endometrial Cancer, Kidney Cancer
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether giving chemotherapy after surgery is more effective than surgery alone in…
- Conditions
- Endometrial Cancer, Kidney Cancer, Ovarian Cancer, Pheochromocytoma
- Trial name
- NCT00002641
- Testing
- filgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- 45 sites in Austria, Belgium and 11 more
- Volunteers
- 350 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Sarcoma
Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have…
- Trial name
- NCT00041236
- Testing
- exatecan mesylate
- Where
- 10 sites in Belgium, Denmark and 2 more
- Volunteers
- 39 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Rhabdomyosarcoma, Osteosarcoma
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
Patients with relapsed solid tumors such as sarcomas and neuroblastoma have a poor survival, generally < 20%. There is an urgent need for new treatments that are safe and effective.
- Conditions
- Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Soft Tissue Sarcoma
- Trial name
- NCT00931931
- Testing
- HSV1716
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Timothy Cripe
Endometrial Cancer, Kidney Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Endometrial Cancer, Kidney Cancer, Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00002764
- Testing
- filgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- Sweden
- Volunteers
- 340 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adipocytic Neoplasm, Liposarcoma
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin…
- Conditions
- Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma
- Trial name
- NCT06239272
- Testing
- Surgical resection, Proton beam radiation therapy, Pazopanib
- Where
- 7 sites in United States
- Volunteers
- 139 people
- Sponsor
- St. Jude Children's Research Hospital
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma
RATIONALE: Glutamine may help prevent mucositis, or mouth sores, in patients receiving chemotherapy for sarcoma. It is not yet known whether glutamine is more effective than a placebo in preventing mucositis in patients receiving…
- Trial name
- NCT00334984
- Testing
- glutamine, chemoprotection, management of therapy complications
- Sponsor
- Children's Oncology Group
Sarcoma, Ewing, Chondrosarcoma
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
This prospective, multi-center, randomized controlled study aims to assess the efficacy of utilizing 3D printed models in preoperative planning for the excision of tumors involving bony structures within the body.
- Conditions
- Sarcoma, Ewing, Chondrosarcoma, Osteosarcoma, Fibrous Histiocytoma
- Trial name
- NCT06387485
- Testing
- 3D Printed Anatomic Model, CT/MRI
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Ricoh USA, Inc.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
- Trial name
- NCT04094610
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 75 people
- Sponsor
- Turning Point Therapeutics, Inc.
Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
This phase III trial is studying observation to see how well a risk based treatment strategy works in patients with soft tissue sarcoma.
- Conditions
- Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma
- Trial name
- NCT00346164
- Testing
- doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery
- Where
- 187 sites in United States, Australia and 3 more
- Volunteers
- 588 people
- Sponsor
- Children's Oncology Group
Neurofibromatosis Type 1
Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs
Neurofibromatosis type 1 (NF1) is a frequent autosomal dominant disorder, caused by heterozygous mutations of the NF1 tumor suppressor gene (chr.17q11.2).
- Trial name
- NCT01218152
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- KU Leuven
Advanced Solid Tumors, Metastatic Pancreatic Cancer
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help.
- Conditions
- Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer
- Trial name
- NCT04222413
- Testing
- Metarrestin
- Where
- 2 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)